ArticleJournal of thoracic disease2025
Grade-driven adjuvant chemotherapy benefit in high-risk stage IB NSCLC: a retrospective cohort study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prognostic Impact of Visceral Pleural Invasion in Node-Negative Non-Small Cell Lung Cancer with Tumors ≤ 3 cm.Cancers · 2026Article
- Biopsies Can Predict Lung Adenocarcinoma IASLC Grade: A New Proposal and Grading Pitfalls.JTO clinical and research reports · 2026Article
- STAS More than a Prognostic Marker-An Evolving Factor in Operative and Adjuvant Treatment Decisions in Early-Stage NSCLC.Cancers · 2026Review
- Adjuvant chemotherapy for completely resected stage IB-IIA non-small cell lung cancer according to the AJCC 8th edition staging system: a real-world retrospective cohort study based on the SEER database.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The benefit of adjuvant chemotherapy (ACT) in stage IB non-small cell lung cancer (NSCLC) remains controversial, particularly for patients with high-risk features [visceral pleural invasion (VPI), lymphovascular invasion (LVI), poor differentiation]. This study aimed to evaluate the efficacy of ACT in this cohort. Methods: We retrospectively analyzed 356 patients with stage IB [American Joint Committee on Cancer (AJCC) 9th edition] lung adenocarcinoma treated from 2016 to 2019, of whom 276 with at least one high-risk factor were included in the study. Propensity score matching (PSM) was used to balance baseline characteristics (n=106 per group). Disease-free survival (DFS) and overall survival (OS) were compared between the ACT and non-ACT groups. Results: ACT significantly improved DFS [hazard ratio (HR) =0.471, P=0.001] and OS (HR =0.519, P=0.03). Subgroup analysis revealed that the benefit was grade-dependent: patients with poorly differentiated (G3) tumors had a 66.5% lower risk of recurrence with ACT (HR =0.335, P=0.001), while those with moderately differentiated (G2) tumors derived no significant benefit (HR =1.041, P=0.91). High-grade histologic patterns (solid, micropapillary, and complex glandular), LVI, and tumor size were independent predictors of poor survival. VPI status did not significantly influence ACT efficacy (P=0.95). Conclusions: ACT provides survival benefits for stage IB NSCLC patients with high-risk features, especially in poorly differentiated (G3) tumors. Histologic grading might serve as a useful tool to guide ACT decisions and to avoid potential overtreatment in moderately differentiated (G2) subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.